Search NLS News

Ultimovacs has announced that the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for  Orphan Drug Designation (ODD) for its therapeutic cancer vaccine UV1 for the treatment of mesothelioma. The designation was granted based on results from the Phase II clinical trial, NIPU evaluating UV1 added to ipilimumab and nivolumab […]

Jeanette Edblad is the new Director of the Office for Life Sciences at the Government Offices in Sweden. NLS asked her about her new role and about Swedish life sciences. Jeanette Edblad has been heading the unit for Entrepreneurship and Innovation, which is responsible for life science issues at the Ministry of Climate and Business. […]

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd that is being investigated to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2. “We are very pleased with the FDA’s decision to grant Fast Track designation for Diamyd and the potential this […]

The two companies have announced the signing of a global license and development agreement, further strengthening their collaboration, following investment from Tolmar in January 2024. Under the terms of the Agreement, Tolmar will obtain a global license to utilize DelSiTech’s proprietary, silica-based, drug delivery technology platform for the development and commercialization of two undisclosed long-acting […]

Catherine J. Wu, of the Dana-Farber Cancer Institute, Boston, USA, is a pioneer in research that may result in the development of personalized vaccines to treat cancer. She is now awarded the Sjöberg Prize, worth one million US dollars, for her work. “I’m a strong supporter and believer in innovation that comes from academic medicine. […]

TILT Biotherapeutics has been selected by the U.S. Department of Defense (DOD) to receive a grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset. The aims of the DOD funded project are to assess safety, signs of efficacy of TILT-123 in combination with pembrolizumab in platinum-resistant/refractory ovarian cancer patients […]

The report, requested by NordForsk, is titled Nordic research infrastructure collaboration – Recommendations for common Nordic activities. The report has been conducted by Professor Sven Stafström from the University of Linköping and former leader of the Swedish Research Council. In the report he investigates research infrastructure activities in the Nordic countries and presents measures that […]

A collaboration agreement between AstraZeneca, Oslo Cancer Cluster, and Oslo Science City aims to strengthen the Nordic health industry by facilitating closer collaboration between researchers, startups, and pharmaceutical companies. The focus on investment in the health industry in Norway gained momentum after Minister of Trade and Industry, Jan Christian Vestre announced at the Norway Life […]

Martin Welschof is currently CEO of BioInvent International. “Martin will be an important contributor as we transition to a clinical stage company and further advance our precision T-cell therapies that have the potential to transform patient outcomes in a range of hard-to-treat solid tumour indications,” says Reagan Jarvis, Co-founder, and CEO, Anocca. Martin Welschof Martin […]

The milestone compensation is related to achieved development goals for the Xork enzyme that Genovis has licensed for therapeutic applications, primarily as a potential pre-treatment in gene therapy but also for autoimmune diseases. Xork was discovered in a subset of streptococci that do not infect humans and the preclinical data generated to date clearly show […]